One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email :PharmaSources@imsinoexpo.com
Whatsapp :+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Favipiravir, as a new broad-spectrum anti-rna virus drug, was approved to be marketed in Japan in March 2014 for the antiviral treatment of influenza a and b.
Research shows that in addition to influenza virus, familavir also shows good antiviral activity against a variety of RNA viruses, such as ebola virus, sand virus, bunya virus, rabies virus.Recent studies have shown that fabivir has a certain inhibitory effect on COVID-19.